Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease
JHEP Reports · 2023-02 · 5 (2) · 100628
DOI: 10.1016/j.jhepr.2022.100628 ↗Kurz gefasst
Fachartikel in der Zeitschrift JHEP Reports, 2023-02. Verfasst von Jingjing Jiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background & Aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), is increasing. Individuals with NASH often develop liver fibrosis and advanced liver fibrosis is the main determinant of mortality in individuals with NASH. We and others have reported that STAT3 contributes to liver fibrosis and hepatocellular carcinoma in mice. Methods: Here, we explored whether STAT3 activation in hepatocyte and non-hepatocyte areas, measured by phospho-STAT3 (pSTAT3), is associated with liver fibrosis progression in 133 patients with NAFLD. We further characterized the molecular and cellular determinants of STAT3 activation by integrating spatial distribution and transcriptomic changes in fibrotic NAFLD livers.Results: pSTAT3 scores in non-hepatocyte areas progressively increased with fibrosis severity (r = 0.53, p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pathology, The University of Texas Medical Branch, Galveston TX, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Jiao, J., Sanchez, J. I., Saldarriaga, O. A., Solis, L. M., Tweardy, D. J., Maru, D. M., Stevenson, H. L., & Beretta, L. (2023). Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Reports, 5(2), 100628. https://doi.org/10.1016/j.jhepr.2022.100628
Vancouver
Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, et al. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Reports. 2023;5(2):100628. doi:10.1016/j.jhepr.2022.100628
BibTeX
@article{Jiao2023,
author = {Jiao, Jingjing and Sanchez, Jessica I and Saldarriaga, Omar A and Solis, Luisa M and Tweardy, David J and Maru, Dipen M and Stevenson, Heather L and Beretta, Laura},
title = {Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease},
journal = {JHEP Reports},
year = {2023},
volume = {5},
number = {2},
pages = {100628},
doi = {10.1016/j.jhepr.2022.100628}
}
EUVIMED